共 50 条
- [31] Ivacaftor for Chronic Obstructive Pulmonary Disease- Results From a Phase 2, Randomized Controlled TrialAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209Vijaykumar, K.Solomon, G. M.Guimbellot, J. S.Acosta, E.Bhambhavni, P.White, S.Kim, H.Raju, S.Rasmussen, L. W.Necole, H.Liu, B.Hathorne, H.Rowe, S. M.Dransfield, M. T.
- [32] Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease A Phase 2 Randomized Clinical TrialJAMA NEUROLOGY, 2020, 77 (03) : 309 - 317Pagan, Fernando. L.Hebron, Michaeline L.Wilmarth, BarbaraTorres-Yaghi, YasarLawler, AbigailMundel, Elizabeth E.Yusuf, NadiaStarr, Nathan J.Anjum, MuhammadArellano, JoyHoward, Helen H.Shi, WangkeMulki, SanjanaKurd-Misto, TarickMatar, SaraLiu, XiaoguangAhn, JaeilMoussa, Charbel
- [33] Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled TrialJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):Tumlin, James A.Lafayette, Richard A.Barratt, JonathanWu Mai-SzuKim, Sung GyunKaufeld, Jessica KatharinaHuang, Shih-Han S.Alamartine, EricPerez Valdivia, Miguel AngelRice, KaraKateifides, AndreasGarlo, KatherineRoccatello, Dario
- [34] Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trialSCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 570 - 570Smith, RCLindenmayer, JPBuga, AMatute, MVaidhyanathaswamy, SButler, E
- [35] Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trialNEUROPSYCHOPHARMACOLOGY, 2004, 29 : S226 - S226Smith, RCLindenmayer, JPBuga, AMatute, MVaidhyanathaswamy, SWarner-Cohen, J
- [36] Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trialEuropean Journal of Nutrition, 2021, 60 : 1633 - 1643James L. DorlingEric RavussinLeanne M. RedmanManju BhapkarKim M. HuffmanSusan B. RacetteSai K. DasJohn W. ApolzanWilliam E. KrausChristoph HöchsmannCorby K. Martin
- [37] Effect of 2 years of calorie restriction on liver biomarkers: results from the CALERIE phase 2 randomized controlled trialEUROPEAN JOURNAL OF NUTRITION, 2021, 60 (03) : 1633 - 1643Dorling, James L.Ravussin, EricRedman, Leanne M.Bhapkar, ManjuHuffman, Kim M.Racette, Susan B.Das, Sai K.Apolzan, John W.Kraus, William E.Hochsmann, ChristophMartin, Corby K.
- [38] Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLDJOURNAL OF HEPATOLOGY, 2024, 80 : S70 - S71Schattenberg, Jorn M.Rozpondek, PiotrOpawska, KrystynaMetivier, SophieLoustaud-Ratti, VeroniqueIbanez-Samaniego, LuisGines, PereBoettler, TobiasBlach, ElzbietaLeeming, DianaKarsdal, MortenProels, MarkusCzarnecki, JudithStiess, MichaelMueller, RalphRomero-Gomez, Manuel
- [39] Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trialHUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)Lopez, PioLopez-Medina, EduardoSaez-Llorens, XavierdeAntonio, RodrigoMasuda, TaiseiMendelman, Paul M.Sherwood, JamesBaehner, FrankBorkowski, Astrid
- [40] SAFETY AND TOLERABILITY CHARACTERIZATION OF MARALIXIBAT IN INFANTS WITH ALGS FROM 2 MONTHS OF AGE: INTERIM RESULTS FROM THE RISE STUDYHEPATOLOGY, 2023, 77 (05) : E135 - E135Gonzales, EmmanuelJankowska, IrenaHorslen, Simon P.Ekong, UdemeRosenthal, PhilipSokal, EtienneLin, Chuan-HaoGarner, WillElliott, JilliannNunes, TiagoThompson, Richard J.